To address the protein change of SPON2 in colon cancer tissues, we performed IHC analyses of SPON2 expression using two commercial independent TMAs, each of which contains 90 cases of colorectal adenocarcinoma. This evidence concerns the gene SPON2 and malignant colon neoplasm.